Metformin hinders metastasis of prostate cancer cells by stimulating the expression of histone methyltransferase SETD2 (SET Domain Containing 2) while decreasing EZH2 (Enhancer of Zeste Homolog 2) and H3K27me3 levels [11]. Here, EZH2 is linked to prostate cancer.